Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in
combination with erlotinib or cetuximab administered to patients with certain types of
cancer.